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1.  Abstract 
The early growth response (Egr) family of transcription factors is composed of four members 
Egr1-4, which play roles in various cell behaviors including proliferation, apoptosis, and 
differentiation in a cell type and stimulus specific manner. Roles for Egr1-3 are especially well 
documented in the nervous system: Egr 1 and 3 regulate expression of genes involved in 
synaptic plasticity and long term potentiation, Egr2 contributes to hindbrain development 
and peripheral nerve myelination, and Egr 1 and 2 also contribute to the transcriptional 
network that drives neuronal differentiation in PC12 cells. However, the mechanisms that 
regulate Egr activity are not fully understood. One mechanism of Egr regulation involves 
interactions with coregulators NGFI-A binding protein 1 and 2 (Nab1 and Nab2). Most studies 
demonstrate that Nab1 and 2 repress Egr transactivation when bound; however, one report 
indicates Nabs can enhance Egr transactivation in a target gene-specific manner. As such, the 
molecular mechanism controlling the effect of Nabs on the activity of Egr1-3 remain unclear. 
Here, we provide evidence that Nab2 is rapidly phosphorylated in PC12 cells following 
treatment with nerve growth factor (NGF) based on an upward mobility shift in Western blot 
that is reversed by phosphatase treatment. The mobility shift was inhibited by the mitogen-
activated protein kinase kinase (MEK) inhibitor (UO126), indicating Nab2 phosphorylation is 
mediated at least in part by extracellular-regulated kinase (ERK). Nine sites on Nab2 that 
match the consensus sequence for ERK phosphorylation were identified and site-directed 
mutagenesis was conducted to generate alanine mutants for each. Unexpectedly, exogenous 
Nab2 was constitutively phosphorylated independent of NGF treatment; nevertheless, the 
Nab2-S126A, -S129A, -S138A, T157A, and -T401A mutants exhibited downward mobility 
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shifts, indicating they are likely phosphorylation sites. Mammalian two-hybrid assays were 
then conducted to detect Nab2-Egr1 interactions and to evaluate whether the mutation of 
each of the phosphorylation sites affect their interactions.  Experiments thus far have tested 
the effect of three Nab2 phosphorylation site mutants (S126A, T157A, and S401A), none of 
which affect Nab2 interactions with Egr1. 
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2. Introduction 
 
2.1 Egr family members are transcription factors 
 
The Egr family of transcription factors are immediate-early genes and consist of four members: 
Egr1 (also known as NGFI-A, Krox-24, Zif-268, Znf225, AT225, G0S30, TIS8), Egr2 (also known as 
Krox-20, AT591, CMT1D, and CMT4E), Egr3 (also known as PILOT), and Egr4 (also known as NGIF-
C, and pAT133). Egr family members contain a conserved DNA binding domain, which is 
composed of three tandem Cys2-His2-type zinc-finger motifs at the carboxyl terminus (figure 1) 
(Christy and Nathans 1989; Pavletich and Pabo 1991). The zinc-finger domain is structured as an 
antiparallel beta pleated sheet and an alpha helix that are held together by a zinc atom and 
hydrophobic residues (figure 2) (Gashler and Sukhatme 1995). There is ninety-percent homology 
within the DNA binding domain of Egr family members, suggesting they bind similar DNA 
sequences and/or similar target genes. Egr family members bind to DNA sequences that are GC-
rich and contain the nine base pair consensus site: 5’-GCG(G/T)GGGCG-3’ (Christy and Nathans 
1989; Nardelli et al. 1991; Patwardhan et al. 1991; Cao et al. 1993). Unlike the carboxyl-terminus, 
the amino terminus of Egr family members is variable. Despite this variability, all Egr family 
members contain an activation domain at the amino terminus through which they activate target 
genes, and the activation domain of Egr1 has been the best characterized (Thiel et al. 2000). Egr1-
3 also contain a conserved repression (R1 domain). NGFI-A binding proteins (Nab1 and Nab2) 
have been shown to bind to the R1 domain and negatively regulate the transcriptional activity of 
Egr1-3 (Russo et al. 1995; Svaren et al. 1996; Thiel et al. 2000).  
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2.2 Induction of Egr family members and their role in the nervous system 
 
Egr family members are induced in response to several stimuli, including growth factors, 
cytokines, neurotransmitters, as well as cell stressors such as hypoxia and oxidative stress 
(O'Donovan et al. 1999; Pagel and Deindl 2012; Thiel et al. 2014). After induction, Egr proteins 
contribute to several different cell behaviors including differentiation, proliferation, and 
apoptosis in a cell-type and stimulus-type specific manner (Khachigian et al. 1997; Lee et al. 2004; 
Pagel et al. 2012). Roles of Egr proteins are particularly well documented in the nervous system.  
One of the original characterizations of Egr1 stemmed from studies on the neuronal 
differentiation of PC12 cells in response to NGF (Milbrandt 1987). PC12 cells are a frequently 
utilized model to investigate the molecular mechanism of neuronal differentiation. Following 
NGF treatment, PC12 cells develop several features that are characteristic of neurons, such as 
cessation of cell proliferation, up-regulation of neuronal genes, neurite outgrowth, and 
development of electrical excitability (Greene and Tischler 1976). Egr1 is induced within 1 hour 
of NGF treatment and is required for subsequent differentiation, as expression of a dominant-
negative Egr blocks differentiation in response to NGF (Levkovitz et al. 2001). Although not fully 
characterized, several Egr1 transcriptional targets that contribute to differentiation have been 
identified, including p35, Arc, Vgf, Sik1, Phlda1, Kctd11, kdm6b, Hbegf, and Ankrd34c (Harada et 
al. 2001; Adams et al. 2017).   
 Another role for Egr1 was discovered from the observation that induction of long term 
potentiation (LTP) in the dentate gyrus of the hippocampus is associated with the rapid induction 
and activation of Egr1 (Cole et al. 1989; Wisden et al. 1990). Egr1 was later shown to play a critical 
role in LTP when Egr1 mutant mice could not maintain LTP induction in the dentate gyrus for 
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longer than 24 hours (Jones et al. 2001).  More recently, overexpression of Egr1 in the forebrain 
of transgenic mice was shown to enhance LTP in the dentate gyrus (Penke et al. 2014). Egr3 is 
also essential for normal LTP and for hippocampal and amygdala-dependent learning and 
memory, as Egr3-deficient mice have profound defects in hippocampal LTP as well as 
hippocampal and amygdala dependent learning and memory (Li et al. 2007). Egr2 mRNA is also 
upregulated in the hippocampus in response to LTP, but it is not associated with increased 
protein levels, suggesting that Egr2 may not play a role in LTP or LTP-associated learning a 
memory (Cheval et al. 2012).  
 Although the role of Egr2 in LTP is unclear, Egr2 is important in hindbrain development. 
Egr2 is expressed in specific hindbrain nuclei in early development of the mouse brain (Wilkinson 
et al. 1989). Egr2 is part of a transcriptional cascade that regulates Hox gene expression which is 
necessary for proper segmentation of the hindbrain during development (Sham et al. 1993).  
Moreover, Egr2 mutant mice die within two weeks after birth because of improper segmentation 
in the hindbrain during development (Schneider-Maunoury et al. 1993).  
 Egr2 is also involved in peripheral nerve myelination. Peripheral myelinating cells 
(Schwann cells) express Egr2 before the onset of myelination and transgenic mice with mutant 
Egr2 have improperly differentiated Schwann cells and incomplete myelination of peripheral 
axons (Topilko et al. 1994). Egr2 expression is maintained in mature myelinating cells (Zorick et 
al. 1996), and the maintenance of peripheral nerve myelination requires continuous Egr2 
expression, as Egr2 knockout mice have hypomyelinated nerves at 4 and 6 weeks of age (Decker 
et al. 2006). In humans,  patients with congenital hypomyelinating neuropathy (CHN) contain one 
dominant or two recessive mutations in Egr2 (Warner et al. 1998).  Further, the severity of patient 
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symptoms in human myelinopathies is directly correlated with the inability of a mutant Egr2 to 
bind DNA (Warner et al. 1999).  
 
2.3 Post-translational regulation of Egr family members 
 
Egr family members can be modified by a variety of post-translational modifications. Mechanisms 
of post-translational modification have been best characterized in Egr1. Egr1 contains a number 
of O- and N-linked glycosylation sites, but little is known about their role except that one N-linked 
glycosylation within the DNA binding domain may regulate Egr1 binding (Muller et al. 1991). Egr1 
is phosphorylated by casein kinase II, tyrosine kinases, and protein kinase C, all of which increase 
the half-life of Egr1 and its DNA binding activity (Cao et al. 1992; Cao et al. 1993; Huang et al. 
1998). In addition, Egr1 is phosphorylated by Akt at two sites (S350 and T309), which is necessary 
for subsequent Egr1 sumoylyation by ARF/sumoylyation ligase (Yu et al. 2004; Yu et al. 2009). 
One study showed that sumoylyation of Egr1 triggered its ubiquitination and consequent 
degradation (Manente et al. 2011). Lastly, Egr1 contains an acetylation site within its DNA binding 
domain that can be acetylated by the p300/CBP complex, which reduces transcriptional activity 
of Egr1 (Yu et al. 2009). 
 
2.4 NGFI-A Binding Proteins (Nab1 and Nab2) are corepressors of Egr1-3  
 
In addition to post-translational modification, Egr1-3 are regulated through protein-protein 
interactions with coregulators Nab1 and Nab2. Nab1 was first identified by its interaction with 
Egr1 and Egr2 in a yeast two-hybrid screen (Russo et al. 1995).  In this study, Nab1 repressed 
transactivation of Egr1 but had no effect on Egr3 activity. Nab2 was later identified as a protein 
with high homology to Nab1 in two domains (figure 3), termed Nab conserved domain 1 (NCD1) 
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and 2 (NCD2) (Svaren et al 1996).  Nab2 similarly acts as a transcriptional corepressor of Egr1-3. 
Nab1 and Nab2 interact with Egr1-3 via the R1 domain (Svaren et al. 1998). Nab corepression of 
Egr1-3 transactivation also involves the recruitment of other proteins. Nab2 interacts with 
chromatin helicase DNA-binding protein 4 (CHD4) through its CHD4-interacting domain (CID) 
(Srinivasan et al. 2006). CHD4 is a subunit of the nucleosome remodeling and deaceteylase 
(NuRD) complex, which represses transcription via histone decaceteylation and nucleosome 
mobilization.  
Although there is much data suggesting that Nab corepressors play a critical role in 
regulation of Egr activity, whether there are molecular mechanisms that govern interactions 
between Nab1-2 and Egr1-3, as well as the effect of Nab on Egr activity upon binding, is largely 
unknown. This study extends our understanding of additional mechanisms that regulate Nab2 
and potentially Egr function.  
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3. Materials and Methods 
 
3.1 Mammalian cell culture 
 
Human brain neuroglioma (H4) cells, rat adrenal medulla pheochromocytoma (PC12) cells, and 
human cervical cancer (HeLa) cells were grown and maintained for experimentation. H4 and HeLa 
cells were maintained in growth medium consisting of Dulbecco’s modification of Eagle’s 
Medium (DMEM) supplemented with 10% fetal bovine serum (FBS) at 37°C and 10% CO2. PC12 
cells were maintained in growth medium consisting of DMEM supplemented with 10% FBS and 
5% horse serum (HS) at 37°C and 10% CO2. For Western blot experiments, 5 x 105 PC12 or H4 
cells were plated per 60 mm dish in 4 mL of growth medium and incubated for 24-48 hours until 
cell harvest. For luciferase assays, 106 PC12 or 5 x 105 HeLa cells were plated per well of a 6-well 
cell culture dish in 2 mL of growth medium and incubated for 24-48 hours until cell harvest.  
 
3.2 Generating Nab2 phosphorylation site mutants 
 
An expression construct containing Nab2 cDNA (pJDM-Nab2) was received from Jeffrey 
Milbrandt at Washington University School of Medicine in St. Louis. The Nab2 cDNA was 
subcloned into the expression vector pcDNA3 (pcDNA3-Nab2) by Kenneth Adams and Sergey 
Kletsov. An oligonucleotide encoding a FLAG tag was also inserted at the 3’ end of the Nab2 cDNA, 
resulting in a pcDNA3-Nab2-FLAG construct. To generate Nab2 phosphorylation site mutants, 
site-directed mutagenesis (SDM) reactions were performed on pcDNA3-Nab2-FLAG to change 
codons for serine/threonine that are situated immediately upstream of a proline residue to 
alanine. SDM reactions were performed to generate nine single site mutants: S114A, S126A, 
S129A, S138A, T157A, S172A, S176A, T401A, and S446A.  Additional SDM reactions were 
performed to generate three double mutants (S126A/S129A, S126A/T401A, and S129A/T401A) 
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and one triple mutant (S126A/S129A/T401A). All SDM reactions were performed using Agilent 
Technologies QuikChange II XL site-directed mutagenesis kit (Agilent Technologies, 200515-5) 
according to manufacturer’s instructions. 
Following SDM, XL-10 Gold Ultracompetent cells (Agilent Technologies, 200517-4) were 
transformed with the products of each SDM reaction according to manufacturer’s instructions 
and spread onto Luria-Bertani (LB) agar plates supplemented with ampicillin at 100 µg/mL. 
Clones from each transformation were isolated and inoculated in 6 mLs of LB broth containing 
Ampicillin at 100 µg/mL. The mutant Nab2 constructs were then purified from broth culture by 
using the QIAprep Spin Miniprep Kit (Qiagen, 27106) according to manufacturers’ instructions. 
To confirm mutagenesis of pcDNA3-Nab2-FLAG at each site, 200-300 ng/µL samples of each 
construct were sent to Eurofins for sequencing using a SP6 or a T7 primer. After confirmation of 
mutagenesis by sequencing, 200 mL of LB Broth containing Ampicillin at 100 ng/mL were 
inoculated with 200 µl of cultures grown for miniprep, and the mutant Nab2 constructs were 
then purified from broth culture by using the QIAprep Spin Maxiprep Kit (Qiagen, 12163) 
according to manufacturers’ instructions.  
 
3.3 Cell Transfection 
 
For Western blot experiments, PC12 (106/60 mm plate), and H4 cells (5 x 105/60 mm plate) were 
plated 24 hours before transfection. Transfection mixtures were prepared containing 500 µl 
DMEM, 10 μl of TransIT-LT1 reagent (Mirus, MIR 2300), and 2 μg of plasmid DNA. The mixtures 
were then incubated for 15-30 min before application to appropriate mammalian cell cultures. 
For luciferase assay, PC12 cells (106/well) or HeLa cells (5 x 105/well) were plated 24 hours before 
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transfection. Transfection mixtures were prepared containing 250 µl DMEM, 5 μl of TransIT-LT1 
reagent (Mirus), and 1-2 μg of total plasmid DNA. The mixtures were then incubated for 15-30 
min before application to each well of the appropriate mammalian cell line. After application of 
transfection mixtures, cultures were incubated at 37°C, 10% CO2 for 24-48 h before harvest.  
 
3.4 Cell harvest and Western blot analysis 
 
Cells were washed twice with 1X phosphate-buffered saline (PBS), lysed directly in 200-300 μl of 
Laemmli buffer, and heated to 100°C for 5 min. Ten to twenty μl of each lysate were loaded and 
electrophoresed through 10 % SDS-polyacrylamide gels, transferred to nitrocellulose 
membranes, and Western blot conducted to detect Nab2-FLAG phosphorylation mutants with 
mouse anti-FLAG (Sigma, F3165, 1:10,000) alongside β-actin with mouse anti-actin antibodies 
(Sigma, A5441, 1:20,000 dilution) as a loading control. Membranes were submerged in blocking 
buffer (5% nonfat dried milk in TBS + 0.2% Tween-20) for 30 min at room temperature, after 
which they were incubated with primary antibody diluted in blocking buffer for 12–18 h at 4°C. 
Membranes were then washed three times for 1 hour in TBS + 0.2% Tween-20 and incubated 
with secondary antibody (goat anti-mouse HRP-conjugate, Bio-Rad, 170–6516, 1:3000 dilution) 
diluted in blocking buffer for 1–2 h at room temperature. Membranes were washed three times 
for 1 hour in TBS + 0.2% Tween-2. Bands were then detected by incubation in  chemiluminescence 
reagent followed by exposure to X-ray film (Western Lightning Plus-ECL, Enhanced 
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3.6 Mammalian two-hybrid assay 
 
Reporter and expression constructs used for mammalian two-hybrid assays were received from 
Dr. John Svaren at the University of Wisconsin-Madison and included (1) a luciferase reporter 
construct with four upstream Gal4 binding sites (Gal4 reporter), (2) an expression construct 
encoding the Egr1 R1 domain fused to the Gal4 DNA binding domain (R1-DBD), and (3) an 
expression construct encoding full length Nab2 fused to the Gal4 activation domain (Nab2-VP16). 
HeLa cells were transfected with 1-2 μg of a total plasmid DNA that consisted of varying 
combinations of: pcDNA3, Gal4 reporter, R1-DBD, Nab2-VP16, and/or Nab2-VP16 
phosphorylation site mutants (phosphorylation mutants were prepared as previously described 
in generating Nab2 phosphorylation site mutants and sequencing was performed as previously 
described but with a CMV forward primer). Cells were harvested 24-48 hours after transfection, 
rinsed once in ice cold 1X phosphate-buffered saline, and resuspended in 100 μL of lysis buffer 
(0.1 M potassium phosphate, pH 7.8, 1% Triton X-100, 1 mM dithiothreitol, 2 mM EDTA). The 
samples were vortexed briefly, incubated on ice for 15 min, and centrifuged in a for 1 min at 
maximum speed to remove cellular debris. The supernatant was then collected and 30 μL of each 
sample was loaded in triplicate in a 96-well plate. Immediately prior to measurement of 
luminescence, 100 μL of assay buffer was added to each well (30 mM Tricine, 3 mM ATP, 15 mM 
MgSO4, 10 mM dithiothreitol, 1 mM D-luciferin, pH 7.8). Luminescence was measured using an 
integration time of 10 seconds using a Synergy II Biotek plate reader with Gen5 software. The 
raw luminescence from two of the triplicate wells were selected and used to calculate the 
average luminescence of each sample. Raw values were converted into fold induction by dividing 
the raw luminescence of the sample (reporter/R1-DBD, reporter/ Nab2-VP16 or reporter/R1-
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DBD/Nab2-VP16) by the raw value of luminescence from reporter alone. Each experiment was 
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4. Results 
 
4.1 Nab2 exhibits a transient mobility shift following NGF treatment 
 
During a previous study investigating the role of Nab2 in neuronal differentiation of PC12 cells, 
Western blot analysis showed an unexpected mobility shift of Nab2 following NGF treatment 
(figure 4).  In the experiment, PC12 cells were treated with NGF for 0-6 hours and subjected to 
Western blot. The upward mobility shift was detected by 1 h, after which the shift gradually 
returned to baseline between 2-6 hours following NGF treatment, suggesting that NGF treatment 
induces a transient post-translational modification of Nab2 in PC12 cells.   
 Although the data presented in figure 4 suggests that Nab2 is post-translationally 
modified in response to NGF, another possibility is that the upper molecular weight bands 
detected after 1 hour of NGF treatment represent newly synthesized Nab2 protein that is larger 
than pre-existing Nab2 in untreated cells. While growth factors induce post-translational 
modification of numerous proteins, they also induce Nab2 transcription and up-regulate global 
protein synthesis rates. Thus it was important to discern whether the upper molecular weight 
Nab2 bands resulted from post-translational modification of pre-existing Nab2 or synthesis of 
Nab2 in a larger (perhaps precursor) form. To test this possibility, Western blot analysis was 
performed on PC12 cells treated with NGF in the presence of cylcoheximide (CHX), which inhibits 
global protein synthesis (figure 5). Nab2 exhibited an upward mobility shift both in the presence 
and absence of CHX, confirming that NGF induces post-translational modification of pre-existing 
Nab2. However, Nab2 levels were higher in the absence of CHX, suggesting that induction of 
Nab2 expression is occurring at the same time as post-translational modification.   
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4.2 Endogenous Nab2 mobility shift is due to ERK-mediated phosphorylation 
 
A variety of post-translational modifications could account for the Nab2 mobility shift (e.g. 
phosphorylation, ubiquitination, and sumoylyation). To evaluate if phosphorylation is the cause 
of the Nab2 mobility shift in response to NGF treatment, PC12 cells were treated with NGF for 
either 10 minutes or 1 hour, lysed, and the cell lysates were treated with lambda protein 
phosphatase prior to Western blot analysis (figure 6). The phosphatase induced a downward 
mobility shift of Nab2 in untreated PC12 cells, suggesting that Nab2 is basally phosphorylated in 
the absence of NGF. Treatment with NGF for 10 minutes or 1 hour induced similar upward 
mobility shifts that were reversed by phosphatase treatment, suggesting that the shifts are due 
to phosphorylation.  
 Previous research has demonstrated that NGF treatment activates two cell signaling 
pathways: (1) Ras/Raf/MEK/ERK and (2) PI-3 kinase/Akt (figure 7).  To determine if ERK signaling 
and/or PI-3 kinase signaling are responsible for Nab2 phosphorylation in response to NGF, the 
effects of a MEK inhibitor (UO126) and a PI-3 kinase inhibitor (LY294002) on the Nab2 mobility 
shift in response to NGF treatment were examined. PC12 cells were pre-treated with UO126 or 
LY294002 for 30 minutes before NGF treatment for an additional 10 minutes or 1 hour. In 
addition, treatments were done in the presence and absence of CHX to ensure that any observed 
mobility shift was not due to differences in Nab2 expression. Following treatments, the cells were 
harvested and subjected to Western blot analysis to evaluate Nab2 mobility (figure 8). UO126 
treatment inhibited the Nab2 mobility shift induced by NGF treatment for 10 minutes or 1 hour 
both in the presence and absence of CHX. LY294002 did not inhibit the Nab2 mobility shift in 
either the presence or absence of CHX. This suggests that ERK signaling is necessary for Nab2 
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phosphorylation and that PI-3 kinase/Akt signaling does not mediate Nab2 phosphorylation in 




























4.3 Exogenous Nab2 is constitutively phosphorylated independent of ERK 
 
Having demonstrated that endogenous Nab2 is phosphorylated in PC12 cells, subsequent 
experiments focused on identifying specific phosphorylation sites on Nab2 by performing 
mutagenesis and transfection. However, before mutating Nab2, the mobility patterns of 
exogenous Nab2 prior to and after NGF treatment were examined alongside the effect of 
phosphatase treatment. An expression construct containing the Nab2 cDNA (pJDM-Nab2) was 
generously donated by Dr. Jeffrey Milbrandt at Washington University, St. Louis.  PC12 cells were 
either untransfected or transfected with pJDM-Nab2 and then treated with NGF for 10 minutes 
(figure 9). Cell lysates were harvested, treated with phosphatase, and Western blot was 
performed. As expected, NGF induced an upward mobility shift of endogenous Nab2 which was 
reversed by phosphatase treatment. However, NGF treatment does not induce an upward 
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mobility shift of exogenous Nab2, indicating that either NGF does not does not induce 
phosphorylation of exogenous Nab2 or NGF-induced phosphorylation does not cause a mobility 
shift. Phosphatase treatment of transfected lysates with or without NGF treatment caused a 
downward mobility shift, indicating that exogenous Nab2 is constitutively phosphorylated when 
expressed in PC12 cells.  
 The basal phosphorylation state of exogenous Nab2 was unexpected. To determine if 
serum starvation is necessary to reduce the phosphorylation state of exogenous Nab2, cells were 
transfected with empty vector or pcDNA3-Nab2-FLAG and serum starved for 0-2 days. Cell lysates 
were harvested and western blot analysis was performed using an anti-FLAG antibody (figure 10). 
A quadruplet banding pattern of Nab2 was observed and the banding pattern was consistent 
throughout 0-2 days of serum starvation. This data suggests that exogenous Nab2 is basally 










































4.4 Identification of nine putative phosphorylation sites on Nab2 
 
The mobility shift of endogenous Nab2 in response to NGF combined with the downward mobility 
shift of endogenous and exogenous Nab2 induced by phosphatase treatment provide strong 
evidence that Nab2 is phosphorylated under basal conditions and further phosphorylated in 
response to NGF treatment. Data from figure 6 indicate that phosphorylation of endogenous 
Nab2 is ERK mediated, but these results could not be replicated with exogenous Nab2 on account 
of the observed constitutive phosphorylation of Nab2 after transfection (figure 10). Despite this 
discrepancy, serine and threonine residues on Nab2 that matched consensus sites for ERK 
phosphorylation were identified as candidate ERK phosphorylation sites. ERK is a proline-directed 
kinase that preferentially phosphorylates serine and threonine residues that lie directly upstream 
of a proline residue (i.e., S/TP sites), with a stronger preference for PXS/TP sites. Nab2 contains 
nine S/TP sites (S114, S126, S129, S138, T157, S172, S176, T401 and S446), two of which match 
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the PXS/TP consensus sequence (S129 and S176). Site directed mutagenesis was performed on 
pcDNA3-Nab2-FLAG at the codon for each of the indicated residues to change the codon for 
serine/threonine to a codon for alanine (table 1). Samples of each mutant plasmid were 
subjected to Sanger sequencing to confirm successful mutation (figure 11).   
 After confirmation of mutagenesis by sequencing, each single site mutant of pcDNA3-
Nab2-FLAG (S114A, S126A, S129A, S138A, T157A, S172A, S176A, T401A, and S446A) was 
transfected into PC12 cells alongside wild-type. Cell lysates were harvested and Western blot 
analysis performed using an anti-FLAG antibody to evaluate the effect of the mutation(s) on the 
mobility patterns of exogenous Nab2 (figure 12). Several mutants exhibited an altered banding 
pattern compared to the quadruplet band pattern of wild-type Nab2-FLAG. Of the nine mutants, 
the S126A, S129A, and T401A exhibited the greatest change, with bands that migrated alongside 
the lower molecular weight bands of wild-type Nab2 FLAG. The S129A mutant also exhibited a 
similar band collapse but it did not appear to be as significant as that seen in S126A and T401A.   
 After observing the effect of S126A, S129A, and T401A on Nab2 mobility, double and 
triple mutants of pcDNA3-Nab2-FLAG at these sites were generated by site-directed 
mutagenesis, which were again confirmed by Sanger sequencing (data not shown).  Each double 
and triple mutant (S126A/S129A, S16A/T401A, S129A/T401A, and S126A/S129A/T401A) was 
transfected into PC12 cells alongside wild-type pcDNA3-Nab2-FLAG, followed by harvest and 
Western blot analysis with anti-FLAG antibody (figure 13). As in previous experiments, the single 
site mutants exhibited similarly collapsed banding patterns. The S126A/S129A double mutant did 
not yield a greater band collapse, while the double mutants with T401A both exhibited greater 
collapse. The triple mutant exhibited the greatest band collapse, yielding a single band that 
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migrated similarly to the lowest molecular weight band detected in the wildtype Nab2-FLAG 
transfections. This data indicates Nab2 is likely phosphorylated at multiple sites, each of which 
contributes to altered mobility of Nab2 in Western blot. 
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4.5 Evaluation of the effect of Nab2 phosphorylation on Nab2/Egr1 interactions using mammalian 
two-hybrid assay 
After demonstrating that Nab2 is phosphorylated and identifying potential phosphorylation sites 
on Nab2, mammalian two-hybrid assays were used to determine whether Nab2 phosphorylation 
affects its ability to form protein-protein interactions with Egr1. The assay entails transfecting 
cells with three constructs: (1) a luciferase reporter with four upstream Gal4 binding sites 
(reporter), (2) an expression construct encoding the Egr1 R1 domain fused to the Gal4 DNA 
binding domain (R1-DBD), and (3) an expression construct encoding full length Nab2 fused to the 
Gal4 activation domain (Nab2-VP16). Following transfection, the R1-DBD fusion protein will bind 
the reporter; if Nab2-VP16 then binds the R1 domain, it will bring the VP16 domain to the 
reporter, resulting in luciferase expression, which can be detected and quantified by luciferase 
assay using a luminometer. 
To first demonstrate Nab2/Egr1 interactions, HeLa cells were transfected with reporter 
alone, reporter + R1-DBD, reporter + Nab2-VP16, or reporter + R1-DBD + Nab2-VP16. Cells were 
then harvested and subjected to luciferase assay to quantify relative luciferase expression levels. 
Luminescence levels from cells transfected with reporter + R1-DBD + Nab2-VP16 increased 
approximately 60-fold compared to reporter alone when 1 ug of total DNA was transfected and 
135-fold when 2 ug of total DNA was transfected (Figure 14). This data suggests that the R1-DBD 
and Nab2-VP16 are interacting and activating transcription to the luciferase reporter, thus 
indicating that the mammalian two-hybrid is working successfully.   
After ensuring that the mammalian two-hybrid could be used to measure interactions 
between Nab2 and the R1 domain of Egr1, mutagenesis was performed on the Nab2-VP16 
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construct in order to use the mammalian-two hybrid assay as a model for investigating the effect 
of Nab2 phosphorylation on its interaction with Egr1. Three single site phosphorylation mutants 
(S126A, T157A, and S401A) of Nab2-VP16 construct were generated using site-directed 
mutagenesis and confirmed by Sanger sequencing as previously described (figure 15).  HeLa cells 
were then transfected with reporter alone, reporter + R1-DBD, reporter + Nab2-VP16 wild-type, 
reporter + R1-DBD + Nab2-VP16 wild-type/S126A/T157A/S401A. Cell were then harvested and 
subjected to luciferase assay.   Luminescence from cells transfected with reporter + R1-DBD + 
wild-type Nab2-VP16 increased approximately 300-fold compared to reporter alone. 
Luminescence from cells transfected with reporter, R1-DBD, and single site Nab2-VP16 
phosphorylation mutants (S126A/T157A/T401A) also increased approximately 250-300 fold 
compared to reporter alone, which did not significantly differ from wild-type Nab2. Altogether, 
this data confirms that protein-protein interactions between Nab2 and the Egr1 R1 domain can 
be detected by the mammalian two hybrid assay and indicates that the interaction is not affected 
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5. Discussion  
 
This study demonstrates that the transcriptional coregulator Nab2 is transiently phosphorylated 
in PC12 cells in response to NGF in an ERK-dependent manner. NGF induced an upward mobility 
shift of Nab2 in Western blot within 10 minutes of treatment, which was reversed by incubating 
cell lysates with lambda protein phosphatase and was inhibited by pre-treatment with a MEK 
inhibitor U0126. The upward mobility shift of Nab2 in response to NGF was not reversed by the 
PI3K inhibitor LY249002. 
Given the effect of NGF treatment on endogenous Nab2, we expected to observe the 
same transient upward mobility shift of exogenous Nab2 following NGF treatment. However, 
Western blot did not show an upward mobility shift of exogenous Nab2 in response to NGF; 
instead, exogenous Nab2 migrated as a quadruplet of bands ranging in size from the lowest 
molecular weight band of endogenous Nab2 before NGF treatment to the highest molecular 
weight band after NGF treatment. Nevertheless, lambda phosphatase treatment of lysates from 
transfectants caused a downward shift of exogenous Nab2 to a molecular weight similar to that 
of endogenous Nab2 before NGF treatment. These data suggest that exogenous Nab2 is basally 
phosphorylated. Serum starvation inhibited ERK activity based on levels of ERK phosphorylation, 
but had no effect on the exogenous Nab2 banding pattern, suggesting that phosphorylation of 
exogenous Nab2 may be ERK-independent. 
Despite the discrepancy in endogenous versus exogenous Nab2 band shifts, potential ERK 
phosphorylation sites were investigated.  ERK is a proline-directed kinase that phosphorylates 
serine or threonine residues that lie directly upstream of a proline residue. Nine potential ERK 
consensus sites were identified within the Nab2 sequence: S114, S126, S129, T157, S172, S176, 
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T401, and S446. After site-directed mutagenesis of each serine/threonine residue to alanine and 
transfection of mutant constructs into PC12 cells, Western blot showed a change in Nab2 banding 
pattern in five phosphorylation mutants: S126A, S129A, S138A, T157A, and T401A. The greatest 
change in banding pattern was seen in the S126A, S129A, and T401A mutants. Double and triple 
phosphorylation mutants at these three sites (S126A/S129A, S126A/S401A, S129A/S401A, 
S126A/S129A/S401A) depicted an additive effect on the banding pattern change of Nab2 in 
Western blot. Of the five phosphorylation mutants that affected the Nab2 banding pattern, four 
lie between the NCD1 and NCD2 domain (S126A, S129A, S138A, T157A) and one is in the CID 
domain (T401A). The area between NCD1 and NCD2 does not have a characterized function, but 
the CID domain modulates Nab2 interaction with CHD4 and the NuRD complex. The Nab2-T401A 
mutant may affect Nab2’s ability to interact with CHD4, which would be an interesting area for 
further study.  
After identifying potential sites of ERK-mediated phosphorylation on Nab2, we examined 
whether Nab2 phosphorylation at these sites would affect its ability to interact with Egr1 using a 
mammalian two-hybrid assay. We first showed that mammalian two-hybrid assay is capable of 
detecting interaction between wild-type Nab2 and the R1 domain of Egr1, and optimized 
conditions for this protocol. We then used site-directed mutagenesis to generate four mutants 
of the Nab2 construct (S126A, T157A, and T401A) and evaluated the effect that the mutation had 
on Egr1 interactions. We found that the interaction between the R1 domain of Egr1 and the 
phosphorylation mutants did not differ from wild-type Nab2.  These findings need to be further 
investigated because consistent clones were not able to be used for experimentation with the 
phosphorylation mutants which could have caused the high variability in luciferase fold induction 
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in the experiments which accounted for the high standard deviation. Nab2-S129A and -S138A 
mutants for mammalian two-hybrid analysis also needs to be generated and evaluated for any 
effect on interactions with the Egr1 R1 domain. Lastly, mammalian two-hybrid assays conducted 
thus far have not included co-transfection with a β-galactosidase expression construct to 
normalize luminescence data for transfection efficiency, which will be included in future 
experiments. 
It is possible that phosphorylation of Nab2 affects its interactions with proteins other than 
Egr1. For example, Nab2 interacts with the CHD4 domain of the NuRD complex, which modulates 
transcriptional repression. Nab2 phosphorylation could potentially alter Nab2 binding to CHD4, 
and this could effect transcriptional repression done by the NuRD complex. In addition, 
phosphorylation of Nab2 could affect Nab2’s interactions with other Nab proteins (Nab1 and 
Nab2).  Nab2 can multimerize with Nab1 or Nab2 through the NCD1 domain, but Nab2 
phosphorylation could modify this interaction. Furthermore, Nab2 has been primarily 
characterized as a corepressor of Egr1, but one study has shown that Nab2 can enhance Egr1 
transactivation. Nab2 phosphorylation could potentially play a role in determining whether or 
not Nab2 activates or represses Egr1 independent of Nab2 directly binding to Egr1.  In conclusion, 
the data presented here provides strong evidence that Nab2 is phosphorylated both basally and 
in response to ERK signaling induced by NGF treatment of PC12 cells. This post-translational 
modification could have a number of effects on Nab2 and its interactions with other proteins in 
the cell. Learning more about the consequence of Nab2 phosphorylation in PC12 cells will be an 
interesting project for future members of the Adams lab.   
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